Sustained Response to Selinexor-Based Therapy for Triple-Class Refractory Multiple Myeloma with Early Relapse After Allogeneic Stem Cell Transplantation

Clinical Practice Points • Selinexor may be active even in the dire situation of early relapse after allogeneic stem cell transplantation. • Selinexor retains activity in patients who are proteasome, immunomodulatory drug, and daratumumab refractory. • Selinexor has the potential to be combined effectively with multiple standard anti-myeloma agents, including carfilzomib.